
Clinical Questions from the Diabetes Clinic-Answers from Big Data

Increasing Prevalence of T2DM in Asia, Latin America, and Africa



International Diabetes Federation. Diabetes Atlas 2019.









5.59pm Wednesday 20th December 2006



192 Member States adopted Resolution 61/225 by consensus

UK/LM/1109/0233

UN Resolution 61/225

The Resolution addresses all diabetes

Diabetes is a chronic, debilitating and costly disease associated with severe complications

Diabetes poses risks to families, Member States and the entire world

UK/LM/1109/0233

UN Resolution 61/225


Diabetes poses challenges to agreed development goals, including MDGs

UN observed World Diabetes Day from 14 November 2007

National policies for prevention, care and treatment of diabetes in line with sustainable development of health-care systems


UK/LM/1109/0233

Diabetes attributable to weight gain (30+yrs)



International Diabetes Federation 2003; International Obesity Task Force, 2003

Prevalence of overweight and obesity in people with type 2 diabetes in England, Wales and Scotland



Overweight refers to BMI 25–29.9 kg/m²; obese refers to BMI ≥30 kg/m²

1. Health and Social Care Information Centre (2013) National Diabetes Audit 2011–2012. Report 1: Care Processes and Treatment Targets. Available at: http://bit.ly/1bk2Glh (accessed 10.02.2014)

2.Scottish Diabetes Survey Monitoring Group (2012) Scottish Diabetes Survey 2012. Available at: http://bit.ly/1gdzGGV (accessed 12.03.2014)

Research: Epidemiology

Obstructive sleep apnoea in Type 2 diabetes mellitus: increased risk for overweight as well as obese people included in a national primary care database analysis

M. Feher, W. Hinton, N. Munro and S. de Lusignan 💿

Department of Clinical and Esperimental Medicine, University of Surrey, Guildford, UK

Accepted 15 April 2019

Abstract

Aims To determine obstructive sleep apnoea prevalence in people with Type 2 or Type 1 diabetes in a national primary care setting, stratified by BMI category, and to explore the relationship between patient characteristics and obstructive sleep apnoea.

Methods Using the Royal College of General Practitioners Research and Surveillance Centre database, a cross-sectional analysis was conducted. Diabetes type was identified using a seven-step algorithm and was grouped by Type 2 diabetes, Type 1 diabetes and no diabetes. The clinical characteristics of these groups were analysed, BMI-stratified obstructive sleep apnoea prevalence rates were calculated, and a multilevel logistic regression analysis was completed on the Type 2 diabetes group.

Results Analysis of 1 275 461 adult records in the Royal College of General Practitioners Research and Surveillance Centre network showed that obstructive sleep apnoea was prevalent in 0.7%. In people with Type 2 diabetes, obstructive sleep apnoea prevalence increased with each increasing BMI category, from 0.5% in those of normal weight to 9.6% in those in the highest obesity class. By comparison, obstructive sleep apnoea prevalence rates for these BMI categories in Type 1 diabetes were 0.3% and 4.3%, and in those without diabetes 1.2% and 3.9%, respectively. Obstructive sleep apnoea was more prevalent in men than women in both diabetes types. When known risk factors were adjusted for, there were increased odds ratios for obstructive sleep apnoea in people with Type 2 diabetes in the overweight and higher BMI categories.

Conclusions Obstructive sleep apnoea was reported in people with both types of diabetes across the range of overweight categories and not simply in the highest obesity class.

Diabet. Med. 36, 1304-1311 (2019)

Table 2. BMI classifications of the adult general practice population with and without diabetes in the RGCP RSC data base

Type 2 DM	Type 1 DM	No diabetes	
N = 84,394	N = 5,443	N = 1,179,730	
574 (0.7)	109 (2.0)	41,533 (3.5)	
13,346 (15.8)	2,085 (38.3)	433,935 (36.8)	
28,275 (33.5)	1,877 (34.5)	328,947 (27.9)	
22,780 (27.0)	866 (15.9)	134,809 (11.4)	
11,089 (13.1)	266 (4.9)	44,908 (3.8)	
7,162 (8.5)	117 (2.1)	22,919 (1.9)	
	N = 84,394 574 (0.7) 13,346 (15.8) 28,275 (33.5) 22,780 (27.0) 11,089 (13.1)	N = 84,394 $N = 5,443$ $574 (0.7)$ $109 (2.0)$ $13,346 (15.8)$ $2,085 (38.3)$ $28,275 (33.5)$ $1,877 (34.5)$ $22,780 (27.0)$ $866 (15.9)$ $11,089 (13.1)$ $266 (4.9)$	

Table 3. Prevalence of obstructive sleep apnoea (OSA) according to BMI category (a) and obesity class (b)

a) BMI category

	OSA, % (95% CI)		
_	Type 2 DM N = 84,394	Type 1 DM N = 5,443	No diabetes N = 1,179,730
Underweight	0.2 (0.00-0.52)	0.0 (0.00-0.00)	0.1 (0.09–0.16)
Normal	0.5 (0.35–0.58)	0.3 (0.10-0.62)	0.1 (0.14–0.16)
Overweight	1.2 (1.08-1.33)	0.7 (0.37-1.17)	0.5 (0.47-0.51)
Obesity (all classes)	4.7 (4.48-4.89)	1.6 (0.96-2.32)	1.7 (1.62–1.73)

b) Obesity class

		OSA , % (95% CI)	
	Type 2 DM N = 84,394	Type 1 DM N = 5,443	No diabetes N = 1,179,730
1	2.8 (2.59-3.02)	1.4 (0.69–2.19)	1.2 (1.13–1.25)
2	5.3 (4.93-5.77)	1.1 (0.00-2.63)	2.0 (1.85-2.10)
3	9.6 (8.95-10.32)	4.3 (0.85-8.55)	3.9 (3.66-4.16)

BMI classifications: underweight <18.5 kg/m²; normal 18.5–24.9 kg/m²; overweight 25.0–29.9 kg/m²; Obesity classes: class 1 30.0–34.9 kg/m²; class 2 35.0–39.9 kg/m²; class 3 ≥40.0 kg/m². BMI, body mass index; CI, confidence interval; DM, diabetes mellitus; OSA, obstructive sleep apnoea

PP929 Demographic and clinical factors for safer pregnancy in diabetes: trends over time in a national primary care study



Mariangela Gaudio^{1,2}, Nicoletta Dozio², Michael Feher¹, Marina Scavini², Simon de Lusignan² L'Automation Constant Agenteurs Medicas, University of Same, Galderi (M. 1), We date for failure (marine), Mari III

BACKGROUND

Pre-conception care for women with diabetes, aimed at optimization of metabolic control, review/withdrawal of specific medications and management of comorbidities, reduces pregnancy complications. However, only a minority of women with diabetes plan their pregnancy and most conceive with negative but modifiable factors.

AIMS


To describe the changes over 13 years of demographic, clinical characteristics, and specific medications in women of childbearing age with diabetes.


MATERIALS & METHODS


Women with diabetes, aged 16-45 years, were identified from the Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC) network. Repeated annual cross-sectional analyses were undertaken between 2004 and 2017 to determine glycaemic control, medications and other conditions. Unfavourable factors for pregnancy:
HbA1c ≥8.5% (69 mmol/mol);
BMI > 30 kg/m²;
Presence of microalbuminuria;
Hypertension or SBP ≥ 140 mmHg or DBP ≥ 90 mmHg regardless of antihypertensive medication;
Prescription of statins, ACE inhibitors or ARB;
Prescription of at least one diabetes medication other than metformin and insulin (for type 2 diabetes patient only).

RESULTS

We identified 3,218 women (61.5% type 2 diabetes) in 2004 and 6,657 (65.0% type 2 diabetes) in 2017.







 The proportion of women with type 1 diabetes with BMI > 30 kg/m2 increased from 19.8% (95%CI: 17.0 – 22.6) to 26% (95%CI: 23.7 – 28.3), while it remained stable among those with type 2 diabetes [66.2% (95%CI: 63.6 – 68.8) to 68.1 (95%CI: 66.3 – 69.8)]. Prescription of medications for therapy of type 2 diabetes other than insulin and metformin increased from 22.3% (95%CI: 20.5 – 24.2) to 27.3% (95%CI: 26.0 – 28.6).

SURREY

 Prescription of ACE inhibitors, ARBs or statins decreased in type 1 diabetes from 21.3% (95%CI: 19.0 – 23.6) to 14% (95%CI: 12.6 – 15.4) and from 34.6% (95%CI: 31.5 – 36.7) to 30.7% (95%CI: 29.3 – 32.0) in type 2 diabetes.

CONCLUSIONS

Despite an overall improvement in glycaemic control, women with diabetes of childbearing age have more than one unfavourable factor/medication in the case of pregnancy. Enhanced educational interventions on pregnancy planning to both healthcare professionals and patients should be implemented to target treatable factors for safer pregnancies.

> Acknowledgements Erasmus+ Traineeship Grant

GLP-1 RA treatment: a benefit-risk analysis from a retrospective cohort study



E. Konstantara¹, A.P. McGovern¹, W. Hinton¹, R. Coyle¹, M. Feher¹, Neil Munro¹, S. de Lusignan¹ ¹Department of Clinical and Experimental Medicine, University of Survey, UK

RC GP General Procession

Background

Glacegon-like peride-1 scorptor agonists (GLP-1 fRA) are an established drug class of injectable non-insult treatment for type 2 diabetes (T2D). Glinical stats have shown various bonofits including reductions in HAAto and weight, and two hypoglycaenia risk, while gastroitestinal side-streats have been identified as a proceminant limiting factor of GLP-1 FAs.¹⁴ Hewevin, it is unclear whether heads factings are generalisable to real world clinical practice, and which patients are more to less likely to respond well to the mediment.

Aims

- To determine the patients managed in a primary care setting most lively to barrelt from GLP-1 RAs, and with the lowest risk of adverse effects.
- 2) To identify the proportion of people from a current national dataset who were ever prescribed a GLP-1 RA.

Methods

We performed a retraspective cohort analysis using a primary care based population (Royal College of General Practitioners Research and Surveillance Centre, N a1,582,443).⁴

We identified a cohort of people with T2D prosofibed at loast one GLP-1 RA therapy (Exeruside, Licisenside, Licisplatide, Albiguide or Dulopticide) up to 31° December 2016. Regression modelling was used to secontain factors associated with: 1 improvement in HeAts:

- 2) weight reduction;
- S) wedu tegropou
- 3) presence of gasticintestinal side-effects (nauses, vomiting, and distributil); and
- 4) heatment discontinuations during the first year.

Adjustments were made for: gender, app, whickly, acciseconomic status (using the index of Multiple Deprivation (MCD), body mass index (SMI), duration of disbetos, and HbA1s at inflation.

Results

From 144,427 people with T2D, 3JP% (n = 5,514) were prescribed one or more GLP+1 RAs, Mean HbAte at GLP+1 RA initiation was 76,05 immolived (SD 15,65) (Table1) with mean HbAte improvement -4,99 minolived (SD 15,90) at 1 year, Mean EMI at initiation was 37,98 kg/m² (SD 7,03) with mean BMI improvement -1.19 (SD 3,15) at 1 year.

Improvement in HbA1e

After adjusting for baseline HBA1c, people 55years old had a greater reduction in HBA1c at 1 year, compared to those < 35 years (35-74 years) -2.63; 95% CI -4.25 to -1.02; 75+ years: -2.612; 55% CI -7.61 to -2.63). Females, compared to mates, showed a greater HBA1c reduction (-1.69) memotimed; 95% CI -3.21 to -0.66). Other associations are shown in Figure 1. Sed operandic terms and IBA1 were not associations to the status and IBA1 were not associated with glycametic terprovement.

Weight reduction

Weight reduction was greater in those with the highest initial BMI (-0.13 kg/m², 35% CI -0.14 to -0.11). There were no other associations identified.

Bide effects

Side offects were almost wice as frequently reported by formales (OR 1.79; 95% CI 1.27 to 2.51). There were no other associations with reporting at adverse effects.

Discontinuation

Treatment dispertinuation was less common in these who had T2D for 1-3 years (OR 0.45; 95% Cl 0.37 to 0.67) and more common in these degraced 10+ years agt (OR 1.72; 95% Cl 1.45 to 2.05) compared to these with T2D for 4.6 years. Thethering dispertinuation was also less levely. In these with a high HbAte at initiation (73.9+ minutime) (OR 0.61; 85% Cl 0.49 to 0.74) compared to these with a high HbAte at initiation (73.9+ minutime) (OR 0.61; 85% Cl 0.49 to 0.74) compared to these with a baser HbAte (47; 557, 4 minutime); and more field; to these with a BMI 2 40 kg/mf. (OR 1.54; 95% Cl 1.21 to 1.97) compared to these with BMI 25.0-29.9 kg/mf.

Chargetoriolito	# [54] OF HEARY
Visia	2,906 (53,2)
Age at the GLP 1 HA	现下:113
Ethnicky recorded	4.779(86.2)
Winte	4,277(27.8)
Acian	240 (5.0)
Harris	140 (2.6)
Mand	38(87)
Ofer	25(0.5)
MD recorded	5.502189.81
MD quirille 5 (least steprived)	1.071(19.4)
MD quinke 6	3,138(20.4)
NO que lie 3	1.121(00.0)
MD quirile 2	1.038(18.8)
MD quintile 1 (most deprived)	1,156 (21.0)
it Mi recorded	0.358(79.8)
BM at feat BLP-1 PA	36.0 :7.03
Duration of diabetes at liver OLP-1 HA	-現1 -10.1
HoAto at Inst GLP-1 RA	76.1 ±18.0

Table 1. Baseline characteristics of people with T2D

ever prescribed a GLP-1 RA (N = 5,514).

Figure 1. Associations between clinical characteristics and HbA1c (mmol/mol) at 1 year after OLP-1 RA Initiation.

Dendor (ref. Male) Fr	ersale	
A	5-74	
(ref. <88 years)	375	-
	Asian	-
	5 ack	and the second second
(ref. White)	Mont	
- 3	Other	
Duration of	1.5	1
cistoriao	2.0	-
juf <1 pars	210	
Holic	c#7.5	
(vel 57.5	-75.8	-
47.5-52.4)	273.9	- House and the second s
	1.2	20 -15 -10 -5 0 5 10 15

HisAlic (rendires)) difference

Conclusions

Older people and these with clabeles of short duration actives the greatest dycasmic benefit from GLP1 RAs. Fernales also have greater HbAte reduction despite reporting more adverse effects. Weight loss appears to be consistent across all groups.

These findings will help develop a targeted approach to GLP-1 PA prescribing in individuals with T2D.

Key findings

- 3.6% of people with T2D ware over prescribed a DLP 1 RA
- Following initiation of GLP-1 RA, both HbA1c and BMI decreased at 1 year.
- Reductions in HbAtc at 1 year were granter in order people (365 years) and these with a siturter duration (41 year) of T2D.
- Formies were more likely to report adverse effects, tait still indeeved a lower HbA1c at 1 year after initiation.
- Discontinuation was less likely with higher HbAlo at initiation, but more likely with higher BMIs.

Acknowledgments

The aution would like to that's allow contributions at the University of Startes Filipa Formal pointer project managers Chick Moose and Jammy van Wymen (Instancem)

References

- Parto M, Rossbauge C, N Engl J Bed, 2010 (2007) 779–779.
 Buas, JK, Henry HM, Ham J, et Al, Dabates Zare, 2004 Mov 22(11) 2829-39.
- Roma (FW, Dataset, Fedrup They 2018 Law 2008) S224-
- 5041. 4. Constit A. Hellon M. McCovers A. et al. 1840 Open. 2010 Apr
- 20.8 H. 4871092

Diabetes Ther (2018) 9:1397-1402 https://doi.org/10.1007/s13300-018-0390-8



STUDY PROTOCOL

Does Real World Use of Liraglutide Match its Use in the LEADER Cardiovascular Outcome Trial? Study Protocol

William Hinton · Michael Feher · Neil Munro · Simon de Lusignan

Received: January 31, 2018 / Published online: March 31, 2018 © The Author(s) 2018

ABSTRACT

Background: Liraglutide is an injectable therapy to treat type 2 diabetes (T2DM), belonging to the glucagon-like peptide-1 receptor agonist class of drugs. The Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial established that liraglutide demonstrated glucose-lowering benefits and improved cardiovascular outcomes in those individuals with T2DM at high cardiovascular risk.


Aims: The aim of this study is to report the prevalence and characteristics of people treated with liraglutide compared with the LEADER trial. In addition, the remaining portion of the T2DM population will be examined to determine the prevalence of those who meet the inclusion criteria for the LEADER trial but who are not treated with this medication.

Study Design and Methods: This is a crosssectional analysis of routinely collected primary care data on all people with T2DM included in the Royal College of General Practitioners (RCGP) Research and Surveillance Center (R network database. People with T2DM will identified from the dataset using a well-est lished ontological process. Read and other cl cal codes will be used to identify pec prescribed liraglutide and those at high care vascular risk. We will use descriptive statistic report the characteristics of people with T2I prescribed liraglutide compared with those of LEADER trial and the proportion of the wi T2DM cohort that matches the LEADER in sion criteria. In terms of ethical consideratic this study used pseudonymized data, and ' classed as an "Audit of current practice".

Planned Outputs: The results of the study be be submitted for publication in a peer-review journal to report the applicability of the ress of the LEADER trial to real-world clin practice.

Funding: Novo Nordisk Limited.

Keywords: Cardiovascular diseases; Cro sectional studies; Diabetes mellitus, type Liraglutide; Medical record syste computerized



General Poster Session

Insulin Therapy in Type 3c Diabetes—More Common in Chronic Rather than Acute Pancreatitis

WILLIAM HINTON, MICHAEL FEHER, NEIL M. MUNRO, RACHEL M. COYLE and SIMON DE LUSIGNAN

+ Author Affiliations

Diabetes 2018 Jul; 67(Supplement 1): -. https://doi.org/10.2337/db18-1047-P



GPrevious

Article Info & Metrics

Abstract

Background and Aims: Prevalence of diabetes following pancreatic disease (type 3c diabetes/T3cDM) is estimated to affect 5-10% of people with diabetes in Western populations. However, misclassification of T3cDM is common. Consequently, there is little real-world data on prescribing of antihyperglycaemic medications in people with T3cDM. The aim of this study is to evaluate prescribing of antihyperglycaemic medications in people with T3cDM.

Research: Treatment

Sodium–glucose co-transporter-2 inhibitor cardiovascular outcome trials and generalizability to English primary care

W. Hinton^{1,2}, M. Feher¹, N. Munro², M. Joy^{1,2} and S. de Lusignan^{1,2,3}

¹Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, ²Department of Clinical and Experimental Medicine, University of Surrey, Guildford and ²Royal College of General Practitioners, Research and Surveillance Centre, London, UK

Accepted 28 February 2020

Abstract

Aim To identify people in English primary care with equivalent cardiovascular risk to participants in the sodiumglucose co-transporter-2 inhibitor (SGLT-2i) cardiovascular outcome trials (CVOTs). A secondary objective was to report the usage of SGLT-2is.

Methods Cross-sectional analysis of people registered with participating practices in the Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC) network on the 31 December 2016. We derived: (1) proportions of the primary care population eligible for inclusion in each SGLT-2i CVOT (CANVAS, DECLARE, EMPA-REG and VERTIS); (2) characteristics of the eligible population compared with trial participants (demographics, disease duration and vascular risk); and (3) differences within the eligible population prescribed SGLT-2is.

Results The proportions of people with type 2 diabetes (N = 84 394) meeting the inclusion criteria for each CVOT were: DECLARE 27% [95% confidence interval (CI) 26.5–27.1]; CANVAS 17% (16.6–17.1); VERTIS 7% (7.1–7.4); and EMPA-REG 7% (6.5–6.8). Primary care populations fulfilling inclusion criteria were 5–8 years older than trial cohorts, and <10% with inclusion criteria of each trial were prescribed an SGLT-2i; a greater proportion were men, and of white ethnicity.

Conclusions There was variation in proportions of the primary care type 2 diabetes population fulfilling inclusion criteria of SGLT-2i CVOTs. The more stringent the inclusion criteria, the lower the proportion identified in a primary care setting. Prescription rates for SGLT-2is were low in this national database, and there were demographic disparities in prescribing.

Diabet. Med. 37, 1499-1508 (2020)

Diabetes Ther (2020) 11:2169-2175 https://doi.org/10.1007/s13300-020-00878-y



STUDY PROTOCOL

Does Renal Function or Heart Failure Diagnosis Affect Primary Care Prescribing for Sodium-Glucose Co-Transporter 2 Inhibitors in Type 2 Diabetes?

William Hinton · Michael Feher · Neil Munro · Simon de Lusignan 🔞

Received: April 28, 2020 / Published online: July 15, 2020 © The Author(s) 2020

ABSTRACT

Introduction: Sodium-glucose co-transporter 2 inhibitors (SGLT2is) are a unique class of drugs currently used in the management of type 2 diabetes (T2D). There are emerging data from cardiovascular outcome trials confirming renal and heart failure benefits of these drugs independent of glucose lowering. By contrast, the current licencing indications of these drugs are

Methods: We will perform a cross-sectional analysis of people with T2D in the Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC) network. The RCGP RSC includes more than 1500 volunteer practices throughout England and parts of Wales, and a representative sample of over 10 million patients. The proportion of adults with T2D ever prescribed an SGLT2i will be determined. Within this cohort, we will calculate the per-

Hypoglycaemia: Making sense of chaotic coding in primary care computerised medical records

W. Hinton^{1,3}, M.D. Feher¹, N. Munro², H. Kasetty³, B.C.T. Field², S. de Lusignan^{1,4}



Harlield Department of Default prior for RE RECEIPT Default Default Orbital, FE Repartment of Default and Examplement Modelins, University of Default AL (Spec Symbol 2018), Default and All States (Spec Symbol 2018) (Spec Symbol 2018), Default and Spec Symbol 2018.

RC GP Republications of General Poststance

Astard & Deelfarce Online

Background

Hypoglycaema is one of the most important sideeffects of imulate, sulphomplaness and megitiniskes¹². If prosens a major barrier to people with disbetes to achieve glucese treatment targets, with the aim to provent diabetes complications. Consistent recording of both asymptomatic and symptomatic hypoglycaemia is crucial to offective clinical management, aducation, and received.

Recently, the American Diabetes Association and the International Hypoglytaemic Study Group have published guidelines to stendardize the recording of hypoglycaemia (Table 11rd, To the best of our knowledge, coding of hypoglycaemia in primary date has not previously been reviewed.

Aims

The aims of the study were to identify the individual codes for hypodycaemia, and troquencies of use for recording any hypodycaemia in the primary care setting.

Methods

We performed a retrospective ophent study using routinely collected primary care data from the Royal College of General Practitioners (PCGP) Research and Sarveillance Centre (PSC) database. The RCGP RSC is a retroesity representative English primary care sentinel network?, which comprised 349,863 people with diabetes (ever registered) at the time that data were extracted (Stat December 2018), from a population of ever tour million people.

We identified each divided code for hypoglycaenia using the standardised UK terminologies: Systematized Nomenclature of Medicine Clinical Terms (SNOMED-CT) and the Read classification. We then determined the frequency of use for each clinical code for any hypoglycaemia in the diabetes cohort, renked their usage, and also exeluated the number of codes used for severe hypoglycaemia.

Results

From 40,185 individuals (comprising 11.5% of the total diabates cohort) with at least one hypoglycaenia event, we ascertained that there were 96,533 repente recordings of a hypoglycaenic optiode. The majority of these overtal occurred in people treated with either insulins, subphorykureas or magRinides (83,8%).

We identified 87 different clinical obtes available to record depetptively the cases of hypoglycasma, However, almost half (n + 41) of the discriptive codes were not used to record a hypoglycasmic event.

These codes accounted for 77.4% of hypoglycaenia recordings ("Last hypoglycaenia attack" 39.7%. Thypoglycaenia unspecified 26.5%. Theguency of hypoglycaenia attacks" (1.3%); while 43 separate codes were used to record 22.6% of hypoglycaenia events (Table 2).

Descriptors for "severe hypoglyceenia" were documented by 10 separate code terms, which comprised 7.7% (r = 7,418) of the hypoglyceenia recordings (Table 3).

Table 1. Recommended classification of hypoglycaumia^{1,4}

Lond	Olycaemic criteria description
Lovel 1	Gloosce 254 mg/dL (3.0 mmol/L) and 275 mg/dL (3.9 mmol/L)
Level 2	Glacase <54 regist. (3.0 mms/k)
Level 3	Severe hypodycaenic event alwest montal and/or physical status requiring events assistance

Table 2. The ten most commonly used code terms to record hypoglycaemia (from total number of hypoglycaemic event recordings; N = 96,533)

Sinkel code term	n (16)
au hypoglyculor ia utach	38,287 (39,7)
lypoglycsen is unspecified	25,565 (26.5)
requercy of hypoglycaemic attacks	10,007 (19.2)
ypoplycaemic wanting good	6,671 (6.7)
requerce of hexpital-treated hypoglycaemia	3.409 (3.6)
Orisolis and oral hypoglycewnic (articlatietic) ruge causing adverse effects in therapeutic une	2.168 (2.2)
requency of GP or parametic treated pophysechia	1.917(2.0)
typophyssem is unspecified NOS	1.769 (1.8)
leactive hypoglycaemia NDS	1,685 (1.7)
Npoglyssem is come	(0.1) 586
ther hypoglycaernia, terms	3,462 (3.8)

Table 3. Code terms to record severe hypoglycaemia (N = 7,418)

Chinical code term	n (%)	
Frequency of hospital-treated hypoglycaensia	3,409 (HE-0)	
Frequency of GP or parametic beated typoplycaemia	2,185 (29.5)	
Hypoplyosemic come	957 (53.0)	
Hypeglyssemic attack requiring 3xt party assistance	602(8.1)	
Hypeglycoartic comu NOS	104(1.4)	
Type 1 debelos mellius with hypoglycsenic cons	62 (0.8)	
Type 2 diobeles mellins with hypoglycoamic comis.	51 (0.7)	
Hypoglycsem a-induced convulsion	23 (0.5)	
Non-insulin dependent diabetes mellious with hypoglycaemic come	14 (0.2)	
inguin coma	1 (0:0)	

Conclusions

Recent guidelines have been published both to attendardiae the recording of hypoglycaemie in clinical trabs and to describe fewer categories for types of hypoglycaemia. In order to harmonise coding for hypoglycaemia in primary care, informatics maybe an important step with improved ontologies (offlerent categories for teachments and conditional to capture the different descriptors of hypoglycaemia.

Key findings

- 11.5% of people with diabetes had at least one seconded hypoplycaemic event.
- There was were verticer in hypophycemia codes used in this primary care national database.
- There were 17 separate clinical codes available to record hypoglycaemia, but only 46 were utilised.
- For severe hypoglycaemic, 10 different code terms were utiliazd.

Acknowledgments

The wathors would like to frank other contributors at the Linkversity of Colord: Filips Fernitra (pentor project manager) Julian Einstrock (ROL), developer (

This research was sponsored by a grant from Novo Nordisk.

References

- 1. McColl, A.L., Endoornol Helpb Clir North Am, 301 2, 41 (1); J. 57-
- Setter: 115 Endocrine Meado Din North Am. 1958, 1811 (2). 195203.
- Harradienal Hepoglycoomia Study Group, Ukabeles Care, 2917. 4071 (p. 155–157.
- Avertan Datees Association Datees Gave 2019, 492(ecpt > p. 508-978
- Comes R., Hinton W. McCovers A. et al. (384) Open. 2010 Apr 2016;41(e01103)2